National Cancer Institute - NCI Division of Cancer Treatment and ...

More documents

Recommendations

Info

program fosters collaborations within the cancer research community and works extensively with the pharmaceutical and biotechnology industries as well. CTEP also reaches out to patients and their advocates to help establish research priorities. ■ Developmental Therapeutics Program (DTP)—serves as a vital resource in discovering potential cancer therapeutics and acquiring preclinical development information. The program provides research materials, including Web-accessible data and tools, vialed and plated compounds, tumor cells, and research animals, and manufactures new agents in bulk quantities for use in investigational new drug (IND)–directed studies. The program is playing a central role in new collaborations with the NCI Center for Cancer Research (CCR) to reinvigorate the cancer drug development pipeline, with the goal of significantly shortening the amount of time it takes to safely develop effective new treatments for patients with cancer. ■ Radiation Research Program (RRP)— supports clinical research by providing expertise to investigators who perform novel radiotherapy research, assisting the radiotherapy research community in establishing priorities for the future direction of radiation research, providing medically underserved communities with access to radiotherapy, and evaluating the effectiveness of radiation research being conducted by NCI grantees. RRP also coordinates its activities with other radiation research programs at NCI, NIH, other federal agencies, and national and international research organizations. Additionally, RRP serves as a focal point for extramural investigators concerned with clinically related radiation research. D I V I S I O N O F C A N C E R T R E A T M E N T A N D D I A G N O S I S ■ 5
DCTD Research Grants 6 ■ P R O G R A M A C C O M P L I S H M E N T S 2 0 0 6 DCTD Research Grants Percent of Grant Dollars Awarded by Mechanism * Percent of Grant Dollars Awarded by Mechanism* Fiscal Year 2005 Fiscal Year 2005 R01 = 36% R03, R13, T15, R15, U56 =
Page 1 and 2: National Cancer Institute U.S. DEPA
Page 3 and 4: ii ■ P R O G R A M A C C O M P L
Page 5 and 6: Clinical trials performed using an
Page 7 and 8: Dr. James H. Doroshow, Director Jam
Page 9: Cancer Diagnosis Program Dr. Sheila
Page 13 and 14: disease-specific steering committee
Page 15 and 16: ■ The DCTD Developmental Therapeu
Page 17 and 18: P A R T N E R S H I P S A N D C O L
Page 19 and 20: laboratories. Dr. Kevin Dobbin, BRB
Page 21 and 22: ■ Gene expression patterns and pr
Page 23 and 24: Simon R. DNA microarrays for diagno
Page 25 and 26: Microarray Myths and Truths Myths
Page 27 and 28: target, is sensitive to the agent.
Page 29 and 30: O T H E R B I O S T A T I S T I C A
Page 31 and 32: almost inevitably leads to an invas
Page 33 and 34: Software and Technical Report Archi
Page 35 and 36: Biomarker Development Process Marke
Page 37 and 38: Strategic Partnering to Evaluate Ca
Page 39 and 40: C U R R E N T F U N D I N G O P P O
Page 41 and 42: P A R T N E R S H I P S A N D C O L
Page 43 and 44: several types of cancer TMAs have b
Page 45 and 46: Courtesy of NCI Visuals Online, Bil
Page 47 and 48: ■ Cooperative Human Tissue Networ
Page 49 and 50: Progress in many areas of cancer re
Page 51 and 52: Diagnostic Imaging Program in 1996,
Page 53 and 54: NCI Visuals Online, Terese Winslow,
Page 55 and 56: ■ Support development and deliver
Page 57 and 58: Small Animal Imaging Resource Progr
Page 59 and 60: C U R R E N T F U N D I N G O P P O
Page 61 and 62:
Quick-Trials for Imaging and Image-
Page 63 and 64:
Association of American Cancer Inst
Page 65 and 66:
Food and Drug Administration and Ce
Page 67 and 68:
Dr. Edward A. Neuwelt, Oregon Healt
Page 69 and 70:
Virtual Colonoscopy Training Collec
Page 71 and 72:
Not only does CTEP identify promisi
Page 73 and 74:
The Clinical Trials Cooperative Gro
Page 75 and 76:
of pediatric cancers and therapeuti
Page 77 and 78:
the front line treatment of chronic
Page 79 and 80:
Quick-Trials for Novel Cancer Thera
Page 81 and 82:
Industry Collaborators Agent Name 7
Page 83 and 84:
Industry Collaborators Agent Name 7
Page 85 and 86:
NCI Visuals Online, George McGregor
Page 87 and 88:
provided for use in this clinical t
Page 89 and 90:
with or without bevacizumab (NSC #
Page 91 and 92:
Oxaliplatin-Based Regimen Permits S
Page 93 and 94:
egular checkups to look for lymph-n
Page 95 and 96:
NCI Visuals Online. Human lymphoma
Page 97 and 98:
T O O L S , P R O D U C T S , A N D
Page 99 and 100:
■ Clinical Trials Monitoring Bran
Page 101 and 102:
DTP’s staff and administered gran
Page 103 and 104:
therapeutics. Proposed exploratory
Page 105 and 106:
M A J O R O N G O I N G I N I T I A
Page 107 and 108:
National Cancer Institute. discover
Page 109 and 110:
C U R R E N T F U N D I N G O P P O
Page 111 and 112:
DTP oversees animal-production faci
Page 113 and 114:
disease can require considerable in
Page 115 and 116:
National Cancer Institute. commerci
Page 117 and 118:
The Type 1 Diabetes Rapid Access to
Page 119 and 120:
H I S T O R Y - M A R K I N G E V E
Page 121 and 122:
With this approach, patients are no
Page 123 and 124:
This included a camptothecin deriva
Page 125 and 126:
RRP supports research involving a v
Page 127 and 128:
Laredo Medical Center, Laredo, TX h
Page 129 and 130:
With TELESYNERGY® as a link, healt
Page 131 and 132:
Radiation Bioterrorism Research and
Page 133 and 134:
Enhanced Radiosensitivity The Molec
Page 135 and 136:
M E E T I N G S A N D W O R K S H O
Page 137 and 138:
Cancer Imaging Program 132 ■ P R
Page 139 and 140:
Cancer Therapy Evaluation Program,
Page 141 and 142:
Developmental Therapeutics Program,
Page 143 and 144:
Developmental Therapeutics Program,
show all

National Cancer Institute - NCI Division of Cancer Treatment and ...

Create successful ePaper yourself

Delete template?

Save as template?